GOSS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
38.4M
+316.0%
9.2M
-45.5%
17.0M
+22.9%
13.8M
+3.8%
13.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
38.4M
+316.0%
9.2M
-45.5%
17.0M
+22.9%
13.8M
+3.8%
13.3M
Operating Expenses
31.2M
-11.5%
35.3M
-42.9%
61.8M
+3.3%
59.8M
-4.1%
62.4M
R&D
21.6M
-18.2%
26.4M
-38.7%
43.1M
-12.0%
48.9M
-7.7%
53.0M
SG&A
9.6M
+8.3%
8.9M
-52.5%
18.7M
+71.9%
10.9M
+16.1%
9.4M
Operating Income
7.2M
+127.6%
-26074000
+41.9%
-44866000
+2.5%
-46039000
+6.3%
-49114000
EBITDA
7.2M
+127.6%
-26070000
+41.9%
-44861000
+14.3%
-52333000
-6.6%
-49108000
Net Income
-48072000
-384.4%
16.9M
+136.2%
-46664000
+1.2%
-47238000
+2.0%
-48221000
EPS (Basic)
$-7.36
-284.0%
$4.00
+125.0%
$-16.00
+1.8%
$-16.29
+3.7%
$-16.92
EPS (Diluted)
$-7.36
-15.0%
$-6.40
+60.0%
$-16.00
+1.8%
$-16.29
+3.7%
$-16.92
Shares (Diluted)
6.5M
+58.9%
4.1M
+40.4%
2.9M
+0.9%
2.9M
+1.8%
2.8M
Gossamer Bio (GOSS) — Financials